Search

BR-102024017765-A2 - Bioformulation based on Lippia origanoides Kunth

BR102024017765A2BR 102024017765 A2BR102024017765 A2BR 102024017765A2BR-102024017765-A2

Abstract

The present invention utilizes a formulation of Lippia origanoides Kunth together with nystatin, amphotericin B, or eucalyptol to have an effect on Candida tropicalis in patients undergoing radiotherapy or chemotherapy. This formulation minimizes the need for enteral or parenteral nutrition for these patients.

Inventors

  • DANIEL FURTADO SILVA
  • ANA CAROLINA LYRA DE ALBUQUERQUE
  • EDELTRUDES DE OLIVEIRA LIMA

Assignees

  • UNIVERSIDADE FEDERAL DA PARAIBA

Dates

Publication Date
20260310
Application Date
20240829

Claims (7)

  1. 1. “Bioformulation based on Lippia origanoides Kunth for the control of Candida tropicalis” characterized by comprising the essential oil of Lippia origanoides, in an appropriate quantity, in which the concentrations can vary between 0.1% and 99%.
  2. 2. “Bioformulation based on Lippia origanoides Kunth for the control of Candida tropicalis” according to claim 1, characterized by containing emulsions, preferably of the oil-in-water type, containing the essential oil of Lippia origanoides.
  3. 3. “Bioformulation based on Lippia origanoides Kunth for the control of Candida tropicalis” according to claims 1 and 2, characterized by containing 20 to 90% of Lippia origanoides plant extract.
  4. 4. “Bioformulation based on Lippia origanoides Kunth for the control of Candida tropicalis” according to claims 1 to 3, characterized by containing 0 to 10% saccharin, but preferably 0.25% saccharin, without excluding other concentrations in the product formulation.
  5. 5. “Bioformulation based on Lippia origanoides Kunth for the control of Candida tropicalis” according to claims 1 to 4, characterized by containing nystatin.
  6. 6. “Bioformulation based on Lippia origanoides Kunth for the control of Candida tropicalis” according to claims 1 to 5, characterized by containing amphotericin B.
  7. 7. “Bioformulation based on Lippia origanoides Kunth for the control of Candida tropicalis” according to claims 1 to 6, characterized by containing eucalyptol.

Description

Field of invention [001] The present invention relates to a formulation of Lippia origanoides Kunth. more specifically, the present invention relates to a formulation of Lippia origanoides Kunth. for use in Candida tropicalis. Background of the invention [002] There are some patent publications for inventions focused on the production of formulations, such as: US2015209401 (A1) which presents several possibilities for the use of Lippia origanoides (sidoides), Pl 0602027-5 A2 which describes formulations based on Lippia essential oil for personal protection against Aedes aegypti. Pl 1002020-9 A2 which describes phytotherapeutic pharmaceutical forms with antimicrobial activity, comprising a mixture of essential oils, in which Lippia oil is present, suitable for the treatment of bovine mastitis. Pl 9805100-8 A2 which describes the production of antimicrobial phytotherapeutics from the Lippia plant species from trunk, inflorescences, leaves and thin branches, BR 102018016526-7 A2, for external otitis in animals. [003] It is known that resistant Candida tropicalis has been studied in immunosuppressed patients undergoing chemotherapy and radiotherapy of the head and neck due to its presence in lesions that cause burning and discomfort during eating. The frequent occurrence of hyposalivation leads to the emergence of secondary infections by Candida albicans, and currently, the presence of Candida tropicalis in place of this has surprised researchers. Several studies have been conducted to introduce new agents against Candida tropicalis. Various substances have been tested to alleviate the symptoms induced by the presence of Candida tropicalis during chemotherapy or radiotherapy treatment, attempting to reduce burning sensations with varying results. Among these substances are Nystatin and Amphotericin B, whose effectiveness has been reduced, necessitating modification through synergism of other substances in the formulation. Objective of the invention [004] The objective of the present invention is to provide a formulation of Lippia origanoides Kunth. together with Nystatin, Amphotericin B or Eucalyptol, aiming to provide greater effectiveness in preventing Candida tropicalis. Summary of the invention [005] In order to solve such problems, the present invention was developed, whereby the formulation of Lippia origanoides Kunth. alone or with the addition of Nystatin, Amphotericin B or Eucalyptol reduces the presence of Candida tropicalis. Detailed description of the invention [006] The basic composition of the mouthwash was made according to the following criteria: Essential oil from the leaves exclusively or manipulated together with Nystatin, Amphotericin B or Eucalyptol whose Minimum Inhibitory Concentration was 64μg/mL.